<DOC>
	<DOCNO>NCT02882087</DOCNO>
	<brief_summary>This phase Ⅱ , placebo-controlled , multicenter , dynamic randomize , double blind study efficacy safety RC18 , recombinant human B lymphocyte stimulate factor receptor-antibody fusion protein subject inadequate response TNF-α antagonist due treat moderate severe rheumatoid arthritis .</brief_summary>
	<brief_title>A Study Efficacy Safety TACI-antibody Fusion Protein Injection ( RC18 ) Subjects With Inadequate Response TNF-α Antagonists Due Treat Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis adult onset RA physician define 1987 and/or 2010 ACR criteria.and ESR C reaction protein ( CRP ) great normal range Aged 1865 year old ; Consent use effective contraception study period ( woman childbearing age ) Patients inadequate response exist therapy least one antiTNFs Infliximab ( Remicade ) least three time , adalimumab ( Humira ) , least four time , etanercept ( Enbrel ) use least 8 week , etanercept use least 8 week .And Last medication time randomization 12 week . Voluntarily sign informed consent ; Patients take MTX least 12 week screen maintain dose stability ≥7.5mg/ week ( equivalent dose ) 4weeks randomization . If subject take DMARDs ( except MTX ) screening , test discontinue least 4 week randomization . If subject receive treatment corticosteroid , must stabilize dose ( dose prednisone ) least equal less 10mg / day 4 week ( randomization ) ; If subject receive treatment NSAIDs , must stabilize dose ( dose prednisone ) least 4 week ( randomization ) . When patient 's condition achieve moderate severe active RA screening , define least 6/68 tenderness joint least 6/66 swollen joint . There serious heart , liver , kidney important organ blood , endocrine system diseases medical history ; Evaluation criterion severity : 1. liver function ≥2 ULN ; 2 . Cr &gt; 135μmol/L ; 3 . WBCs &lt; 3x 109/L ; ; 4. hemoglobin &lt; 85g/L ; 5. platelet count &lt; 80x 109/L . Have historically active hepatitis active hepatitis medical history ; HBsAg surface antigen positive patient allow select , anti HBC single positive add HBVDNA quantitative detection , HBVDNA quantity negative regarded exclusion ; Immune deficiency , uncontrolled severe infection patient active recurrent peptic ulcer ; pregnant , lactating woman men woman birth plan past 6 month ; Have history allergic reaction contrast agent parenteral administration human biological medicine . Receipt live vaccine within 1 month ( except herpes zoster vaccine ) Have participate clinical trial first 28 day initial screen 5 time halflife period study compound ( take time elderly ) . Patients use biological agent treatment DMARDs within three month Infection herpes zoster HIV virus screening ; Active TB screening.Exception patient PPD≥15mm.But Patients anti tuberculosis treatment 3 year without relapse allow participate trial ; Malignant tumor patient : patient suffer malignant tumor remove recurrence cervical carcinoma situ evidence metastatic disease basal cell squamous cell carcinoma completely remove least 3 year without recurrence participate . history longterm alcohol abuse , intravenous drug abuse illicit drug abuse within 6 month Planning surgery RA significant surgery period study . patient experience follow event within 12 week screening : myocardial infarction , unstable ischemic heart disease , stroke , New York Heart Association class IV heart failure Patients receive interferon treatment ( interferon alpha , intron alpha , pegintron , double talon , intergen , Pegasys etc . ) within 4 week screening , expect test period need accept interferon therapy . The combined use immunosuppressive agent associate organ transplantation allow study period . Combined non RA systemic inflammatory disease , include limiting , juvenile chronic arthritis , vertebral arthrosis , limited enteritis ( Crohn 's disease ) , ulcerative colitis , psoriatic arthritis , activity vasculitis gout . But secondary drying syndrome patient need exclude . Investigator consider candidate appropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>